The DOI matches its Crossref record; 113 of the 113 references it cites were found in a registry or an index.
Issues and progress with protein kinase inhibitors for cancer treatment
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 1×
“5% improvement in overall survival among 469 metastatic breast cancer patients with HER2-overexpressing tumours (a molecular abnormality that occurs in 25–30% of breast cancer”
BackgroundMutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
The protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056
The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621
Blume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Bhattacharjee, A., Richards, W. G., Staunton, J., Li, C., Monti, S., Vasa, P., Ladd, C., Beheshti, J., Bueno, R., Gillette, M., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191502998 · Cited by 2,576
Cited by
Tumorigenesis and the angiogenic switch
Bergers, G., & Benjamin, L. E. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1093 · Cited by 3,559
A small molecule–kinase interaction map for clinical kinase inhibitors
Fabian, M. A., Biggs, W. H., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1068 · Cited by 1,892
Wilhelm, S. M., Adnane, L., Newell, P., Villanueva, A., Llovet, J. M., & Lynch, M. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0013 · Cited by 1,459
Protein Kinase Inhibitors: Insights into Drug Design from Structure
Noble, M. E. M., Endicott, J. A., & Johnson, L. N. (2004) · Science · doi:10.1126/science.1095920 · Cited by 1,198
Comparing antibody and small-molecule therapies for cancer
Imai, K., & Takaoka, A. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1913 · Cited by 792
Mechanisms of cutaneous toxicities to EGFR inhibitors
Lacouture, M. E. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1970 · Cited by 789
ABC Transporters in Multidrug Resistance and Pharmacokinetics, and Strategies for Drug Development
Choi, Y., & Yu, A.-M. (2014) · Current Pharmaceutical Design · doi:10.2174/138161282005140214165212 · Cited by 629
Reconstruction of cellular signalling networks and analysis of their properties
Papin, J. A., Hunter, T., Palsson, B. O., & Subramaniam, S. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1570 · Cited by 532
Protein phosphatase 2A regulatory subunits and cancer
Eichhorn, P. J. A., Creyghton, M. P., & Bernards, R. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2008.05.005 · Cited by 513
Ward, P., Equinet, L., Packer, J., & Doerig, C. (2004) · BMC Genomics · doi:10.1186/1471-2164-5-79 · Cited by 507
Liao, J. J.-L. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm0608107 · Cited by 507
Raymond, E., Alexandre, J., Faivre, S., Vera, K., Materman, E., Boni, J., Leister, C., Korth-Bradley, J., Hanauske, A., & Armand, J.-P. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.116 · Cited by 499
Mechanisms of sarcoma development
Helman, L. J., & Meltzer, P. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1168 · Cited by 460
Targeted Therapies for Hepatocellular Carcinoma
Villanueva, A., & Llovet, J. M. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.03.006 · Cited by 449
Protein Flexibility in Ligand Docking and Virtual Screening to Protein Kinases
Cavasotto, C. N., & Abagyan, R. A. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.01.003 · Cited by 412
The Hedgehog's tale: developing strategies for targeting cancer
Ng, J. M. Y., & Curran, T. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3079 · Cited by 398
The ErbB/HER receptor protein-tyrosine kinases and cancer
Roskoski, R. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.04.150 · Cited by 395
Li, Z., Hao, P., Li, L., Tan, C. Y. J., Cheng, X., Chen, G. Y. J., Sze, S. K., Shen, H., & Yao, S. Q. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201300683 · Cited by 366
Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.
Neumann, J., Zeindl-Eberhart, E., Kirchner, T., & Jung, A. (2009) · Pathology - Research and Practice · doi:10.1016/j.prp.2009.07.010 · Cited by 361
GOLLOB, J., WILHELM, S., CARTER, C., & KELLEY, S. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.04.002 · Cited by 360
RET as a Diagnostic and Therapeutic Target in Sporadic and Hereditary Endocrine Tumors
de Groot, J. W. B., Links, T. P., Plukker, J. T. M., Lips, C. J. M., & Hofstra, R. M. W. (2006) · Endocrine Reviews · doi:10.1210/er.2006-0017 · Cited by 356
Lynch, T. J., Kim, E. S., Eaby, B., Garey, J., West, D. P., & Lacouture, M. E. (2007) · The Oncologist · doi:10.1634/theoncologist.12-5-610 · Cited by 341
Strategies to overcome resistance to targeted protein kinase inhibitors
Daub, H., Specht, K., & Ullrich, A. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1579 · Cited by 334
MacCallum, D. E., Melville, J., Frame, S., Watt, K., Anderson, S., Gianella-Borradori, A., Lane, D. P., & Green, S. R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0233 · Cited by 288
The neurobiology of gliomas: from cell biology to the development of therapeutic approaches
Westphal, M., & Lamszus, K. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3060 · Cited by 286
Kornblau, S. M., Womble, M., Qiu, Y. H., Jackson, C. E., Chen, W., Konopleva, M., Estey, E. H., & Andreeff, M. (2006) · Blood · doi:10.1182/blood-2006-02-003475 · Cited by 265
Skin toxicities associated with epidermal growth factor receptor inhibitors
Li, T., & Perez-Soler, R. (2009) · Targeted Oncology · doi:10.1007/s11523-009-0114-0 · Cited by 261
Loh, S. H. Y., Francescut, L., Lingor, P., Bähr, M., & Nicotera, P. (2008) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402258 · Cited by 108
Ishikawa, T., Takahashi, K., Ikeda, N., Kajimoto, Y., Hagiya, Y., Ogura, S.-I., Miyatake, S.-I., & Kuroiwa, T. (2011) · Pharmaceutics · doi:10.3390/pharmaceutics3030615 · Cited by 34
An, R., Hagiya, Y., Tamura, A., Li, S., Saito, H., Tokushima, D., & Ishikawa, T. (2009) · Pharmaceutical Research · doi:10.1007/s11095-008-9738-5 · Cited by 34
Saito, H., An, R., Hirano, H., & Ishikawa, T. (2010) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.25.72 · Cited by 7
Metadata
- Authors
- Dancey, J., & Sausville, E. A.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2003-04-01
- Volume
- 2
- Issue
- 4
- Pages
- 296-313
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1993860023
- Cited by
- 526
- References
- 113
- FWCI
- 5.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.